Interest in microdosing as an approach to health enhancement has increased significantly in recent years.

Among adults who use psychedelics, most notably psilocybin, microdosing has become increasingly prevalent.

No research shows microdosing psychedelics to be effective for enhancing mental-emotional well-being.

Because potency and dosing are unpredictable, people may end up consuming considerably more than they expect.

Microdosing as an approach to health enhancement has become more common recently, with social media influencers touting its benefits, and even advertisements for certain GLP-1 medications advocating it. Almost any drug can be microdosed—all it requires is to substantially reduce the prescribed/recommended dosage. In the case of psychedelics, microdosing is generally defined as taking a small-enough dose to not induce acute effects—the intention is to avoid producing an altered state of consciousness.

According to a new RAND study, in 2025 an estimated 10 million U.S. adults microdosed psilocybin, LSD, or MDMA. Beyond microdosing, the study also examined the use of 11 different psychedelic substances among adults in the U.S. In 2025 the five most used psychedelic substances in order were: psilocybin (11 million adults), MDMA (4.7 million), Amanita muscaria mushrooms (3.5 million), ketamine (3.3 million), and LSD (3 million).[1]

There has been increasing interest in the effects of microdosing psychedelics on mental health and well-being, but until now little information has been available about its prevalence. The RAND researchers found that among adults who use psychedelics, microdosing is common. Among those who used psilocybin in the past year, 69 percent microdosed at least once during that 12-month period. Of the more than 200 million total days of psilocybin use reported during 2025, nearly half involved microdosing.

What constitutes a microdose?

With increasing interest in the use of psychedelics for therapeutic purposes, this information about the prevalence of microdosing has important implications for research, public health, and regulatory considerations. Yet, there’s no agreed-upon standard as to what constitutes a microdose. The RAND study defined it as taking a fraction of a regular dose that’s much lower than one would take if the intention was to experience altered perception, hallucinations, or a “trip” that characterize psychedelic experiences. Because the dosage is sub-acute (and in turn assumed to be perfectly safe), microdosing is often repeated over a period of multiple days, weeks, or even months.

There are a variety of reasons people report for microdosing psychedelics. In the RAND study a common expressed motivation was self-treatment for depression and anxiety, along with other mental health conditions. As understandable as that impulse may be, it’s nonetheless cause for concern.

While psilocybin and MDMA have shown real promise in randomized controlled trials to treat PTSD, severe depression, addiction[2] and even chronic pain[3], they have yet to be FDA approved for any of these disorders. Importantly, these clinical trials were conducted under tightly controlled conditions. Participants underwent careful medical and mental health screening. The psychedelic dosing was carefully structured and occurred only in supervised clinical settings. Participants were closely monitored for six to eight hours after taking the drugs. They also received intensive psychotherapy before, during, and after administration to help them process the experience. Moreover, participants in controlled clinical trials typically receive just one to three doses spaced months apart.

Is there any evidence to support the efficacy of microdosing psychedelics?

Obviously, none of these controlled conditions and safeguards are present for people who microdose on their own. Although the use of psilocybin and certain other psychedelics is legal in some states and increasingly accepted overall, the effects of psychedelics can precipitate or exacerbate severe mental-emotional reactions, including acute anxiety/panic, mania, and even psychotic symptoms.

Moreover, people may not even know what they are taking. Psilocybin is a controlled substance that remains illegal to distribute in all but two states, yet products claiming to contain it are readily available in dispensaries, vape shops, gas stations, and across the internet. This is also true for other commonly used psychedelics, which are largely illegal and whose quality and production standards are unknown. As a result, because potency and dosing are inconsistent and unpredictable, someone intending to take a dose that does not cause an altered state of consciousness might end up consuming considerably more than they expect. Due to the absence of any rigorous quality control, products may also contain other undisclosed substances, increasing the risk of unintended and potentially serious adverse effects.

None of these concerns seem to be inhibiting consumer interest. A 2024 JAMA Network Open study found that internet searches for psychedelic microdosing increased more than 13-fold between 2015 and 2023.[4]Anecdotal evidence suggests that rather than attempting to treat a distressing condition, many of those who microdose are hoping to enhance mental sharpness and boost creativity. But the data simply don’t support such hopes. A 2026 meta-analysis of 14 studies found no overall cognitive benefit from microdosing psychedelics. To the contrary, users showed a significant decrease in cognitive control.[5]

Importantly, there is no existing research that demonstrates microdosing psychedelics is effective for treating mental health conditions or for enhancing mental-emotional well-being. Furthermore, the belief that microdosing is safe and effective can prevent people from pursuing more beneficial and proven treatments. If the goal is increased mental clarity and improved mood, they are better off pursuing evidence-based approaches, such as self-calming and emotional regulation practices, regular physical activity, and strengthening social connections.

Copyright 2026 Dan Mager, LCSW

[1] https://www.rand.org/pubs/research_reports/RRA4334-1.html

[2] https://www.psychologytoday.com/us/blog/some-assembly-required/202209/p…

[3] https://www.psychologytoday.com/us/blog/some-assembly-required/202405/p…

[4] Yang KH, Satybaldiyeva N, Allen MR, Ayers JW, Leas EC. State Cannabis and Psychedelic Legislation and Microdosing Interest in the US. JAMA Health Forum. 2024;5(6):e241653. doi:10.1001/jamahealthforum.2024.1653

[5] Netta Pinhas, Nofar Eidlman, Avigail Barnea, Leehe Peled-Avron, Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis, Neuroscience & Biobehavioral Reviews, Volume 180, 2026, 106493,, ISSN 0149-7634, https://doi.org/10.1016/j.neubiorev.2025.106493.

There was a problem adding your email address. Please try again.

By submitting your information you agree to the Psychology Today Terms & Conditions and Privacy Policy

© Psychology Today